Kezar Life Sciences Inc KZR:NASDAQ

Kezar Life Sciences (KZR) said a phase 2 clinical trial evaluating zetomipzomib for active lupus nephritis, a kidney inflammation, showed that 11 of 17 patients achieved an overall renal response of at least 50% reduction in urine protein to creatinine ratio at six months.

Six patients achieved a complete renal response, the company said. Shares were up 46% by Monday afternoon as trading volume surged to more than 35.3 million from its daily average of roughly 1.35 million.

Aviat Networks (AVNW) said it submitted a non-binding offer to acquire all the shares of Ceragon Networks (CRNT) it does not already own for $2.80 per share in cash.

Shares of Ceragon, whose third-largest stockholder is Aviat, jumped 23% after intraday volume soared to over 8.34 million from its daily average of about 456,000.

Decibel Therapeutics (DBTX) said topline data from a phase 1b trial evaluating DB-020 in cancer patients receiving cisplatin chemotherapy showed 87% of patients, who experienced ototoxicity in one ear, were protected from it in the other ear treated with DB-020.

Ototoxicity is a chemotherapy side-effect that can lead to hearing loss. Shares of the company jumped 25% amid an increase in intraday trading volume to 416,000 versus its daily average of over 72,000.